The 10-second takeaway
For the quarter ended March 31 (Q1), ViroPharma missed slightly on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped to a loss.
Margins contracted across the board.
ViroPharma reported revenue of $107.1 million. The 12 analysts polled by S&P Capital IQ hoped for sales of $109.0 million on the same basis. GAAP reported sales were 21% lower than the prior-year quarter's $135.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.15. The four earnings estimates compiled by S&P Capital IQ predicted $0.20 per share. Non-GAAP EPS of $0.15 for Q1 were 40% lower than the prior-year quarter's $0.25 per share. GAAP EPS were -$0.98 for Q1 compared to $0.26 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.1%, 430 basis points worse than the prior-year quarter. Operating margin was 6.0%, much worse than the prior-year quarter. Net margin was -59.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $111.0 million. On the bottom line, the average EPS estimate is $0.19.
Next year's average estimate for revenue is $463.1 million. The average EPS estimate is $0.82.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,198 members out of 1,237 rating the stock outperform, and 39 members rating it underperform. Among 307 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 301 give ViroPharma a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $33.67.
- Add ViroPharma to My Watchlist.